A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette's syndrome.

Mov Disord 2012 May 7;27(6):775-8. Epub 2012 Mar 7.

Atlantic Neuroscience Institute, Overlook Hospital, Summit, New Jersey 07902, USA.

Background: Dopamine agonists could theoretically normalize the suspected central dopamine hypersensitivity in Tourette's syndrome.

Methods: There was a multicenter randomized, placebo-controlled, double-blind clinical trial of pramipexole given for 6 weeks in 63 children and adolescents with Tourette's syndrome.

Results: There were no significant differences in the adjusted mean change in the Total Tic Score of the Yale Global Tic Severity Scale for patients treated with pramipexole (-7.16) and placebo (-7.17). There were no significant treatment effects on change from baseline in the Global Severity score of the Yale Scale and parent- and investigator-scored Clinical Global Impression of Improvement. In patients with attention deficit hyperactivity disorder, there was improvement in DuPaul ADHD scale scores for patients receiving pramipexole compared with placebo.

Conclusions: There was no evidence that pramipexole has efficacy in suppressing tics. Pramipexole may decrease symptoms of associated attention deficit hyperactivity disorder.

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.24919DOI Listing
May 2012
10 Reads

Publication Analysis

Top Keywords

score yale
8
attention deficit
8
hyperactivity disorder
8
trial pramipexole
8
clinical trial
8
randomized placebo-controlled
8
deficit hyperactivity
8
multicenter randomized
8
pramipexole
6
yale global
4
global tic
4
tic severity
4
severity scale
4
impression improvement
4
global impression
4
scale patients
4
total tic
4
adjusted change
4
differences adjusted
4
patients attention
4

Similar Publications